{"pmid":32396018,"title":"Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice.","text":["Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice.","J Cutan Med Surg","Georgakopoulos, Jorge R","Vender, Ron","Yeung, Jensen","32396018"],"journal":"J Cutan Med Surg","authors":["Georgakopoulos, Jorge R","Vender, Ron","Yeung, Jensen"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396018","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1177/1203475420928382","keywords":["covid-19","apremilast","dermatology","psoriasis"],"locations":["Canadian"],"countries":["Canada"],"countries_codes":["CAN|Canada"],"topics":["Prevention"],"weight":1,"_version_":1666627827965886465,"score":9.490897,"similar":[{"pmid":32434413,"title":"Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.","text":["Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.","J Cutan Med Surg","Georgakopoulos, Jorge R","Yeung, Jensen","32434413"],"journal":"J Cutan Med Surg","authors":["Georgakopoulos, Jorge R","Yeung, Jensen"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434413","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1177/1203475420930223","keywords":["covid-19","dermatology","dupilumab","psoriasis"],"topics":["Prevention"],"weight":1,"_version_":1667521393624875008,"score":160.78221},{"pmid":32475151,"title":"Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto.","text":["Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto.","J Cutan Med Surg","Georgakopoulos, Jorge R","Yeung, Jensen","32475151"],"journal":"J Cutan Med Surg","authors":["Georgakopoulos, Jorge R","Yeung, Jensen"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32475151","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1177/1203475420930226","keywords":["covid-19","biologics","dermatology","psoriasis"],"topics":["Prevention"],"weight":1,"_version_":1668437834946576384,"score":144.44872},{"pmid":32424891,"title":"Opportunistic virus infections in psoriasis patients: the safer alternative of apremilast.","text":["Opportunistic virus infections in psoriasis patients: the safer alternative of apremilast.","Dermatol Ther","Armesto, Susana","Gonzalez Vela, Carmen","Gonzalez Lopez, Marco Antonio","32424891"],"journal":"Dermatol Ther","authors":["Armesto, Susana","Gonzalez Vela, Carmen","Gonzalez Lopez, Marco Antonio"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424891","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/dth.13618","keywords":["covid-19","apremilast","psoriasis"],"topics":["Prevention"],"weight":1,"_version_":1667252838038765569,"score":128.34003},{"pmid":32475036,"title":"Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.","text":["Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.","Time to improvement is a crucial characteristic for effective treatments of chronic inflammatory conditions, such as psoriasis. Apremilast is a recently approved drug, belonging to the small molecule phosphodiesterase 4 inhibitors, whose optimal safety and efficacy profile is somewhat affected by slow activity rate in clinical trials. Real world case series are suggesting a more consistent improvement, and with this additional personal investigation on 48 patients, we signal that 58% of patients achieved PASI50, and 19% PASI75 improvement in the first 8 weeks of treatment. Results at 16-week are remarkable, with overall 55% of patients achieving PASI 75, 21% PASI 90 and 14% PASI 100. Only 8 patients (18, 6%) had slightly improved, although satisfied with the regimen, and determined to continue. Noteworthy, our population was rather problematic in terms of comorbidities (86%), and resistance to other treatments, with only 28% naive to systemics, including biologics. Moreover, the observation period includes the Italian outbreak of COVID-19 epidemic, and further information on apremilast safety are provided, no one of the patients having stopped treatment. In such a critical period, the apremilast satisfactory speed of therapeutic response in a real-world setting has further strengthens patient's compliance to remain safely at home, which is the best strategy to limit contagion. This article is protected by copyright. All rights reserved.","Dermatol Ther","Melis, Daniele","Mugheddu, Cristina","Sanna, Silvia","Atzori, Laura","Rongioletti, Franco","32475036"],"abstract":["Time to improvement is a crucial characteristic for effective treatments of chronic inflammatory conditions, such as psoriasis. Apremilast is a recently approved drug, belonging to the small molecule phosphodiesterase 4 inhibitors, whose optimal safety and efficacy profile is somewhat affected by slow activity rate in clinical trials. Real world case series are suggesting a more consistent improvement, and with this additional personal investigation on 48 patients, we signal that 58% of patients achieved PASI50, and 19% PASI75 improvement in the first 8 weeks of treatment. Results at 16-week are remarkable, with overall 55% of patients achieving PASI 75, 21% PASI 90 and 14% PASI 100. Only 8 patients (18, 6%) had slightly improved, although satisfied with the regimen, and determined to continue. Noteworthy, our population was rather problematic in terms of comorbidities (86%), and resistance to other treatments, with only 28% naive to systemics, including biologics. Moreover, the observation period includes the Italian outbreak of COVID-19 epidemic, and further information on apremilast safety are provided, no one of the patients having stopped treatment. In such a critical period, the apremilast satisfactory speed of therapeutic response in a real-world setting has further strengthens patient's compliance to remain safely at home, which is the best strategy to limit contagion. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Melis, Daniele","Mugheddu, Cristina","Sanna, Silvia","Atzori, Laura","Rongioletti, Franco"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32475036","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/dth.13722","keywords":["covid-19","psoriasis","apremilast","efficacy","safety"],"locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1668341932742410241,"score":127.55848},{"pmid":32449265,"title":"Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.","text":["Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.","Dermatol Ther","Yu Olisova, O","Anpilogova, E M","Svistunova, D A","32449265"],"journal":"Dermatol Ther","authors":["Yu Olisova, O","Anpilogova, E M","Svistunova, D A"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32449265","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/dth.13668","keywords":["covid-19","pde-4 inhibitor","sars-cov-2","apremilast","psoriasis"],"topics":["Case Report"],"weight":1,"_version_":1667785213953966080,"score":123.39289}]}